GSK today announced that Triumeq (generic name: dolutegravir, abacavir and lamivudine all-in-one tablet), the innovative antiretroviral (ARV) drug by its subsidiary joint venture ViiV Healthcare1, was officially launched in mainland China.
Press releases -葡京网址pj58881com-34545.com
These press releases are intended for business journalists and analysts/investors
GSK supports the launch of “New Respiration and Frequent Care” online management platform for asthma patients in China
Supported by GSK, “New Respiration and Frequent Care”, Online Management Platform for Patients with Asthma in China (“the project”) was launched today in Guangzhou to improve the asthma control level.
Supported by GSK, "Happy Breath", COPD Tiered Diagnosis and Treatment Project (“the project”) was launched in Beijing today.
Total EPS 24.8p, +49% AER, +46% CER; Adjusted EPS 32.5p, +3% AER, flat CER.
Flixotide Nebules (generic name: Fluticasone Propionate Nebuliser Suspension) has been approved by the China Food and Drug Administration (CFDA), for the treatment of mild to moderate asthma acute exacerbations in children and adolescents aged 4 – 16 years.
ViiV Healthcare1, a joint venture in which GSK is the majority shareholder, released the interim results from the DAWNING study2 at the recent International AIDS Conference
GSK China partners with Ali Health to launch innovative online service platform to improve adult vaccination consultation experience
Today, GSK China and Ali Health jointly announced a strategic partnership to launch an innovative adult vaccination service system.
GSK today announced that Triumeq (generic name: dolutegravir, abacavir and lamivudine all-in-one tablet), the innovative antiretroviral (ARV) drug by its subsidiary joint venture ViiV Healthcare1, was granted approval by the China Food and Drug Administration (CFDA).
Today, on the occasion of World Hepatitis Day, under the guidance and support of the National Health and Family Planning Commission (NHFPC), GSK and the China Health Promotion Foundation (CHPF) signed a Letter of Intent.